Guangdong Provincial Hospital of Chinese Medicine
广东省中医院
Listed for 22 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Guangdong Provincial Hospital of Chinese Medicine
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌5 papers led
- Hepatocellular carcinoma肝细胞癌25 papers led
- Stomach cancer胃癌12 papers led
- Lung cancer肺癌41 papers led
- Pancreatic cancer胰腺癌6 papers led
- Breast cancer乳腺癌50 papers led1 open trial led
- Glioma胶质瘤12 papers led
- Osteosarcoma骨肉瘤2 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
- Neuroblastoma神经母细胞瘤3 papers led
- Ewing sarcoma尤文肉瘤1 paper led
- Beta thalassaemiaβ 地中海贫血0 papers led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病4 papers led
- Myasthenia gravis重症肌无力0 papers led
- Coronary heart disease冠心病15 papers led
- Congenital heart disease先天性心脏病7 papers led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
- Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症4 papers led
- IgA nephropathyIgA 肾病6 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
Not listed for: Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Takayasu arteritis, Hepatic echinococcosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
24 hospitals in Guangzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led5
- Clinical Study of Tuhuanglian Liquid Wet Compress on Acute Radiation Dermatitis of Nasopharyngeal Carcinoma.
- Therapeutic association and mechanistic exploration of modified Sijunzi Decoction in radiation-induced sinusitis: an integrated retrospective analysis and network pharmacology study.
- Efficient T staging in nasopharyngeal carcinoma via deep Learning-Based Multi-Modal classification.
- Survival analysis of a comprehensive treatment strategy for internal carotid artery blowout syndrome by nasopharyngeal carcinoma.
- Prognostic generalization of multi-level CT-dose fusion dosiomics from primary tumor and lymph node in nasopharyngeal carcinoma.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)4
- ASO Visual Abstract: Endoscopic Transoropharyngeal Retropharyngeal Lymph Node (RPLN) Dissection for RPLN Recurrence Nasopharyngeal Carcinoma
- Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway
- PD-1 Combined with VEGF/VEGFR2 Inhibitors for the Re-Treatment of Metastatic Nasopharyngeal Carcinoma
- Survival Follow-Up Analysis of EBBA Treatment Strategy for Internal Carotid Artery Invasion by Nasopharyngeal Carcinoma
Cancer
Hepatocellular carcinoma
肝细胞癌Led 25 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
15 hospitals in Guangzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingComputer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07170345
Age 18 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai
- RecruitingPrediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
- Phase
- Not given
- Started
- 2023-11
- Posted
- Registry
- NCT06157060
Age 18 years to 75 years (registered criteria)
Led by Zhujiang Hospital; 3 listed hospitals as study sitesGuangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led25
- Triptolide impacts CSF1R expression and reprograms the suppressive function of myeloid-derived suppressor cells via targeting the ER stress pathway.
- Identification and validation of an explainable machine learning model for hepatocellular carcinoma at high risk: a retrospective multicenter cohort study.
- Simultaneous versus sequential transcatheter arterial chemoembolization combined with microwave ablation for hepatocellular carcinoma: A retrospective propensity score-matched analysis.
- Molecular subtyping and therapeutic prediction of hepatocellular carcinoma based on exosome proteomics.
- Nano-pectic polysaccharide from vinegar-baked Radix Bupleuri enhances methotrexate efficacy against hepatocellular carcinoma via BCRP and MRP2 downregulation.
- The combination of serum lncRNA PTTG3P and mRNA PTTG1 serves as a diagnostic and prognostic marker for hepatocellular carcinoma.
- Decoding the possible mechanism of action of Paeoniflorigenone in combating Aflatoxin B1-induced liver cancer: an investigation using network pharmacology and bioinformatics analysis.
- Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) T cells by increasing CD122+CXCR3+PD-1- memory T cells.
- The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells.
- Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning.
- Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.
- Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma.
- Comparison of structure and the synergistic anti-hepatocellular carcinoma effect of three polysaccharides from vinegar-baked Radix Bupleuri.
- Surgical resection versus thermal ablation after intra-arterial conversion therapy for unresectable hepatocellular carcinoma: a multicenter retrospective one as per the STROBE guidelines.
- Multiparametric MRI based deep learning model for prediction of early recurrence of hepatocellular carcinoma after SR following TACE.
- Rapid evaluation of hepatocellular carcinoma by detecting plasma exosomes with time-resolved fluorescence immunochromatographic test strips.
- Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study.
- Tanshinone IIA modulates cancer cell morphology and movement via Rho GTPases-mediated actin cytoskeleton remodeling.
- The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials.
- Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis.
- Shentao Ruangan formula promotes apoptosis via the E2F2-p53 pathway in hepatocellular carcinoma.
- Crosstalk of LncRNA HOTAIR and SP1-mediated repression of PDK1 contributes to β-Elemene-inhibited proliferation of hepatocellular carcinoma cells.
- Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway.
- MIL-1, a novel antitumor agent derived from natural product millepachine, acts as tubulin polymerization inhibitor for the treatment of hepatocellular carcinoma.
- Identification of metabolism genes related to hepatocarcinogenesis and progression in type 2 diabetes mellitus via co-expression networks analysis.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status3
Cancer
Stomach cancer
胃癌Led 12 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.
- Open trials led
- 0
- recruiting or about to
15 hospitals in Guangzhou for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
- Not yet recruitingAcupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
- Phase
- N/A
- Started
- 2025-08
- Posted
- Registry
- NCT07098949
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Yiqi Huayu Jiedu formula inhibits JAK2/STAT3-mediated partial EMT in treating chronic atrophic gastritis.
- Feasibility and value of modular splenic hilar lymphadenectomy technique in laparoscopic total gastrectomy: a retrospective-controlled research.
- Transthoracic single-port-assisted laparoscopic gastrectomy versus laparoscopic transhiatal approach for Siewert type II adenocarcinoma of the esophagogastric junction: a single-center retrospective study.
- Electro-acupuncture for health-related quality of life and symptoms in patients with gastric cancer undergoing adjuvant chemotherapy (EAGER): a protocol for a multicenter randomized controlled trial.
- Risk factors for surgical site infection in patients with gastric cancer: A meta-analysis.
- Hand-sewn esophagojejunostomy in transthoracic single-port assisted laparoscopic esophagogastrectomy for Siewert type II adenocarcinoma of the esophagogastric junction with esophageal invasion > 3 cm.
- Quantitative parameters in novel spectral computed tomography: Assessment of Ki-67 expression in patients with gastric adenocarcinoma.
- Transthoracic Single-Port Assisted Laparoscopic Five-Step Maneuver Lower Mediastinal Lymphadenectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction.
- Whether the infracardiac bursa protect right pleura during laparoscopic radical operation of Siewert type II adenocarcinoma of esophagogastric junction?
- Diet and gastric cancer risk: an umbrella review of systematic reviews and meta-analyses of prospective cohort studies.
- Acupuncture for Quality of Life in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy.
- Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL‑6/JAK/STAT3‑mediated PD‑L1 activity.
Chinese-language papers (not in the count)5
- [A retrospective study on an innovative modular surgical technique in laparoscopic total gastrectomy combined with spleen-preserving hilar lymphadenectomy].
- [Gastric hamartomatous inverted polyps: a clinicopathological analysis of five cases].
- [A case report of gastric adenocarcinoma of fundic gland type as suspected gastric neuroendocrine tumor].
- [Safety and feasibility of intrathoracic modified overlap esophagojejunostomy in laparoscopic radical resection of Siewert type Ⅱ adenocarcinoma of esophagogastric junction].
- [Safety and feasibility of laparoscopic double-flap technique in digestive tract reconstruction after proximal gastrectomy for esophagogastric junction tumors larger than 5 cm].
All its trials on ClinicalTrials.gov, any status16
- FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis
- Laparoscopic Total Gastrectomy With Versus Without Bursectomy
- Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal Metastatis
- Laparoscopic Bursectomy and D2 Lymphadenectomy vs.Laparoscopic D2 Lymphadenectomy in Advanced Gastric Cancer
- Laparoscopic-assisted Total Gastrectomy Versus Open Total Gastrectomy With Splenic Hilum Lymph Nodes Dissection
- Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios
- Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
- Acupuncture for QoL and Symptoms in Gastric Cancer During Adjuvant Chemotherapy
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- Effect of Acupuncture for QoL in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy: a Pilot Study
- Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
- Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.
- Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)
- Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2
Cancer
Lung cancer
肺癌Led 41 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.
- Open trials led
- 0
- recruiting or about to
17 hospitals in Guangzhou for lung cancer251 hospitals in China for lung cancer
Open trials with this hospital 6
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingElectro-Acupuncture in Lung cancER : EALER Study
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07337096
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou
- RecruitingPulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07348965
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingBefotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07709585
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingEfficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
- Phase
- N/A
- Started
- 2022-06
- Posted
- Registry
- NCT05378334
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingStudy of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT04930432
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- Not yet recruitingA Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07338396
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Guangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led41
- Exploring the mechanisms of Hu-gu-xiao-ji formula and its components for treatment on non-small cell lung cancer using UPLC-QTOF-MS/MS, network pharmacology, and experiments.
- Fuzheng Kang'ai Formula suppresses NSCLC by inducing a functional crosstalk between autophagy and ferroptosis via EZH2/DOT1L/H3K79me2 signaling.
- Ginsenoside F3 alleviates T cell exhaustion via RIPOR2-mediated immunometabolic reprogramming to potentiate anti-PD-1 therapy.
- Design, synthesis, and biological evaluation of Osimertinib-Cy7 (OSA-Cy7) conjugate as potential theranostic agent targeting activating EGFR mutations.
- Bevacizumab-associated glomerular microangiopathy: a case report and literature review.
- Risk factors for brain metastasis in lung cancer: an umbrella review of systematic reviews and meta-analyses.
- Polyphyllin I induces ferritinophagy dependent ferroptosis through EZH2 and promotes anti-tumor immunity.
- Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms.
- Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports.
- Serum taurine affects lung cancer progression by regulating tumor immune escape mediated by the immune microenvironment.
- Xiaoji decoction induces apoptosis in lung cancer cells and M1 Macrophage polarization via the JAK1/STAT3/PD-L1 pathway.
- Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway.
- Hu-gu-xiao-ji formula reprograms macrophage polarization and suppresses tumor growth to improve non-small cell lung cancer with bone metastasis via multiple signaling pathways.
- Acupuncture reduced incidence of insomnia symptoms in patients with lung cancer: a retrospective cohort study.
- Unraveling impact and potential mechanisms of baseline pain on efficacy of immunotherapy in lung cancer patients: a retrospective and bioinformatic analysis.
- Complete Response of Locally Advanced Lung Adenocarcinoma Following Basil Combined With Cisplatin Plus Pemetrexed Chemotherapy: A Case Report.
- Efficacy and Safety of Huachansu as an Adjuvant Therapy for Non-Small Cell Lung Cancer: An Overview of Systematic Reviews and Meta-Analyses.
- Integrated microbiome and metabolome analysis reveals synergistic efficacy of basil polysaccharide and gefitinib in lung cancer through modulation of gut microbiota and fecal metabolites.
- Exploring the Mechanism of Ferroptosis Induction by Sappanone A in Cancer: Insights into the Mitochondrial Dysfunction Mediated by NRF2/xCT/GPX4 Axis.
- FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
- Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation.
- BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
- SOX2-associated signaling pathways regulate biological phenotypes of cancers.
- Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer.
- The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review.
- Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy.
- Kaempferol promotes non-small cell lung cancer cell autophagy via restricting Met pathway.
- Sinomenine hydrochloride bidirectionally inhibits progression of tumor and autoimmune diseases by regulating AMPK pathway.
- Lung cancer organoids, a promising model still with long way to go.
- Dissecting the ferroptosis-related prognostic biomarker and immune microenvironment of driver gene-negative lung cancer.
- Renal Metastasis from Squamous Cell Carcinoma of the Lung.
- Fuzheng Kang' ai decoction inhibits cell proliferation, migration and invasion by modulating mir-21-5p/human phosphatase and tensin homology deleted on chromosome ten in lung cancer cells.
- Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer.
- Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer.
- Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
- Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
- Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer.
- Periodontal disease and the risk of prostate cancer: a meta-analysis of cohort studies.
- Combined Metabolomics with Transcriptomics Reveals Important Serum Biomarkers Correlated with Lung Cancer Proliferation through a Calcium Signaling Pathway.
- A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
- Apoptotic activities of brusatol in human non-small cell lung cancer cells: Involvement of ROS-mediated mitochondrial-dependent pathway and inhibition of Nrf2-mediated antioxidant response.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status10
- Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
- Electro-Acupuncture in Lung cancER : EALER Study
- A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
- Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
- Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
- Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
- Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Acupuncture for Enhancing Immunotherapy in Advanced NSCLC:a Pilot Study
- Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
- Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.
Cancer
Pancreatic cancer
胰腺癌Led 6 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Guangzhou for pancreatic cancer192 hospitals in China for pancreatic cancer
No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- Dysregulated autophagy at the nexus of type 2 diabetes mellitus and pancreatic cancer pathogenesis.
- PELI1 overexpression contributes to pancreatic cancer progression through upregulating ubiquitination-mediated INPP5J degradation.
- HTF4 modulates the transcription of GID2 to promote the malignant biological behavior of pancreatic cancer.
- Aberrant expression of PELI1 caused by Jagged1 accelerates the malignant phenotype of pancreatic cancer.
- Extracellular vesicles in pancreatic cancer immune escape: Emerging roles and mechanisms.
- Glucagonoma syndrome with atypical necrolytic migratory erythema.
Chinese-language papers (not in the count)1
Cancer
Breast cancer
乳腺癌Led 50 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.3%.
17 hospitals in Guangzhou for breast cancer219 hospitals in China for breast cancer
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Enrolling by invitationEndoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07352137
Age 18 years to 70 years; women only (registered criteria)
Led by Guangdong Provincial Hospital of Chinese MedicineGuangzhou
- RecruitingEfficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Phase
- Not given
- Started
- 2022-10
- Posted
- Registry
- NCT06551220
Age 18 years to 80 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai
- RecruitingEffect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2021-06
- Posted
- Registry
- NCT04790305
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led50
- Effect of HER2-Low Expression on the Efficacy of CDK4/6 Inhibitors in Breast Cancer: A Meta-Analysis.
- Target validation and drug discovery for TNBC: Targeting the Lin28B/Let-7/PBK with the ponicidin.
- Xiaoyao San reverses the pro-breast cancer effect of depression by inhibiting glutamate levels in intestinal flora.
- Ultrasound-Based Deep Learning Radiomics Nomogram for Tumor and Axillary Lymph Node Status Prediction After Neoadjuvant Chemotherapy.
- The risk of dementia in breast cancer survivors: a meta-analysis of observational studies.
- Prediction of intraductal cancer microinfiltration based on the hierarchical fusion of peri-tumor imaging histology and dual view deep learning.
- Machine learning algorithms predict breast cancer incidence risk: a data-driven retrospective study based on biochemical biomarkers.
- Molecular mechanisms of bone metastasis in breast cancer based on transcriptomic and microbiomic analysis.
- Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients.
- Role of low-density cholesterol and Interleukin-17 interaction in breast cancer pathogenesis and treatment.
- Small protein ERSP encoded by LINC02870 promotes triple negative breast cancer progression via IRE1α/XBP1s activation.
- Effect of Huaier granule on prognosis of breast cancer: A single-center propensity score matching retrospective study.
- Extra-skeletal Ewing's sarcoma with EWSR1::ERG translocation of the breast: a case report.
- Ultrasound-based radiomic nomogram for predicting the invasive status of breast cancer: a multicenter study.
- BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer.
- Atractylodes macrocephala Koidz. Polysaccharide Alleviates Chemotherapy-Induced Depression-Like Behaviors Through the Gut-Brain Axis.
- Liquiritin in Aiduqing formula inhibits breast cancer neoangiogenesis by suppressing CTSK-mediated lysosomal degradation of CXCL1 in tumor-associated macrophages.
- The chemosensitizing activity of betulinic acid in suppressing macrophage polarization through GSK-3β/β-catenin/CXCL1 signaling in breast cancer.
- Predicting the axillary lymph node tumor burden in breast cancer patients using ultrasonic radiomics nomogram model.
- Intraoperative ultrasound-guided wire(IOUS-wire) localization biopsy versus preoperative fine needle aspiration cytology(FNAC) for early breast cancer with clinically positive nodes, a retrospective cohort study.
- Clinical and radiological evaluation of a phyllodes tumor of the breast: a case report.
- Tanshinone I improves TNBC chemosensitivity by suppressing late-phase autophagy through AKT/p38 MAPK signaling pathway.
- Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.
- Tumor-associated macrophages/C-X-C motif chemokine ligand 1 promotes breast cancer autophagy-mediated chemoresistance via IGF1R/STAT3/HMGB1 signaling.
- Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.
- Baohuoside I chemosensitises breast cancer to paclitaxel by suppressing extracellular vesicle/CXCL1 signal released from apoptotic cells.
- Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism.
- Female patients with hepatitis B may exhibit a reduced risk of breast cancer: A review of NHANES data.
- XIAOPI formula inhibits chemoresistance and metastasis of triple-negative breast cancer by suppressing extracellular vesicle/CXCL1-induced TAM/PD-L1 signaling.
- The mediating effect of perceived social support between family resilience and meaning in life in breast cancer patients.
- ASO Author Reflections: A More Effective Radiotherapy Modality for Early Breast Cancer: Intraoperative Radiotherapy as a Tumour Bed Boost Combined with Whole Breast Irradiation.
- Intraoperative Radiotherapy as a Tumour-Bed Boost Combined with Whole Breast Irradiation Versus Conventional Radiotherapy in Patients with Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
- Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions.
- Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway.
- Cefoselis enhances breast cancer chemosensitivity by directly targeting GRP78/LRP5 signalling of cancer stem cells.
- 10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling.
- A Delphi Study of Expert Consensus on Chinese Medicine Syndrome Differentiation and Herbal Use for Early Breast Cancer.
- Naringenin in Si-Ni-San formula inhibits chronic psychological stress-induced breast cancer growth and metastasis by modulating estrogen metabolism through FXR/EST pathway.
- An Unsupervised Learning-Based Regional Deformable Model for Automated Multi-Organ Contour Propagation.
- Chronic psychological stress promotes breast cancer pre-metastatic niche formation by mobilizing splenic MDSCs via TAM/CXCL1 signaling.
- A novel incision technique of a totally implanted venous access port in the upper arm for patients with breast cancer.
- Incidence and management of pyrotinib-associated diarrhea in HER2-positive advanced breast cancer patients.
- 1H-NMR based metabolic study of MMTV-PyMT mice along with pathological progress to screen biomarkers for the early diagnosis of breast cancer.
- Crosstalk between Depression and Breast Cancer via Hepatic Epoxide Metabolism: A Central Comorbidity Mechanism.
- Cross-platform genomic identification and clinical validation of breast cancer diagnostic biomarkers.
- Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
- Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration.
- Chinese Medicine Syndromes and Stages of Early Breast Cancer: Hierarchical Cluster Analysis and Implication for Clinical Practice.
- The Effectiveness of Tai Chi in Patients With Breast Cancer: An Overview of Systematic Reviews and Meta-Analyses.
- Aiduqing formula suppresses breast cancer metastasis via inhibiting CXCL1-mediated autophagy.
Chinese-language papers (not in the count)2
All its trials on ClinicalTrials.gov, any status6
- Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision
- Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China
- Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
- Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients
Cancer
Glioma
胶质瘤Led 12 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Guangzhou for glioma187 hospitals in China for glioma
No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led12
- LRP5 enhances glioma cell proliferation by modulating the MAPK/p53/cdc2 pathway.
- MRI-based habitat radiomics for preoperatively predicting IDH status in gliomas.
- A review of traditional Chinese medicine Curcumae Rhizoma for treatment of glioma.
- An overview of Twist1 in glioma progression and recurrence.
- Radiomic Analysis of Contrast-Enhanced MRI Predicts DNA Copy-Number Subtype and Outcome in Lower-Grade Gliomas.
- A novel model based on necroptosis-related genes for predicting immune status and prognosis in glioma.
- Lower-Grade Gliomas: Predicting DNA Methylation Subtyping and its Consequences on Survival with MR Features.
- Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.
- Development of MR-based preoperative nomograms predicting DNA copy number subtype in lower grade gliomas with prognostic implication.
- Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.
- Multimodal imaging in the differential diagnosis of glioma recurrence from treatment-related effects: A protocol for systematic review and network meta-analysis.
- Network pharmacological mechanism of Cinobufotalin against glioma.
Cancer
Osteosarcoma
骨肉瘤Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
30 hospitals in Guangzhou for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Guangzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Chinese-language papers (not in the count)1
Cancer
Neuroblastoma
神经母细胞瘤Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
22 hospitals in Guangzhou for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Establishment and clinical application of a candidate reference measurement procedure for quantification of urinary vanillylmandelic acid and homovanillic acid using ID-LC-MS/MS method.
- The causal relationship between gut microbiota and neuroblastoma: a bidirectional Mendelian randomization analysis and meta-analysis.
- Hydroxysafflor Yellow A Exerts Neuroprotective Effect by Reducing Aβ Toxicity Through Inhibiting Endoplasmic Reticulum Stress in Oxygen-Glucose Deprivation/Reperfusion Cell Model.
Cancer
Ewing sarcoma
尤文肉瘤Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Guangzhou for Ewing sarcoma134 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Blood disorders
Beta thalassaemia
β 地中海贫血Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
18 hospitals in Guangzhou for beta thalassaemia133 hospitals in China for beta thalassaemia
No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 4 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.8%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Guangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and mixed connective tissue disease: a case report.
- Social alienation and related factors in patients with neuromyelitis optica spectrum disorder: a cross-sectional study.
- A meaningful exploration of ofatumumab in refractory NMOSD: a case report.
- The risk factors of neuropathic pain in neuromyelitis optica spectrum disorder: a retrospective case-cohort study.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Myasthenia gravis
重症肌无力Led no English-language PubMed papers on myasthenia gravis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Guangzhou for myasthenia gravis89 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
Other diseases
Coronary heart disease
冠心病Led 15 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.3%.
- Open trials led
- 0
- recruiting or about to
10 hospitals in Guangzhou for coronary heart disease231 hospitals in China for coronary heart disease
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- Not yet recruitingYiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07803471
Age 40 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Zhengzhou
- Not yet recruitingOptimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- Phase
- N/A
- Started
- 2021-09
- Posted
- Registry
- NCT04995159
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led15
- Causal association between lipoproteins and risk of coronary artery disease-a systematic review and meta-analysis of Mendelian randomization studies.
- Causality between Cholecystectomy, Blood Lipids, and Major Adverse Cardiac and Cerebrovascular Events: A Multimodal Approach Highlighting Lipid Regulation.
- Comprehensive Analysis Based on Genes Associated With Cuproptosis, Ferroptosis, and Pyroptosis for the Prediction of Diagnosis and Therapies in Coronary Artery Disease.
- Causal effects between gut microbiota and coronary heart disease: A Mendelian randomization study.
- Giant right coronary artery aneurysm with right coronary artery-right atrial fistula.
- Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanism of Qushi Huatan Decoction Against Coronary Heart Disease.
- Development and Validation of Prediction Models for All-Cause Mortality and Cardiovascular Mortality in Patients on Hemodialysis: A Retrospective Cohort Study in China.
- Cardiovascular involvement in Epstein-Barr virus infection.
- Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis.
- Ferritinophagy in vascular endothelial cells regulated by nanoparticles may benefit the prevention of atherosclerosis and in-stent restenosis.
- Correlation between Characteristics of Coronary Plaque and Chinese Medicine Syndromes of Coronary Heart Disease: A Cross-Sectional Study Analysed by Intravascular Ultrasound.
- CALM1 rs3179089 polymorphism might contribute to coronary artery disease susceptibility in Chinese male: a case-control study.
- Application value of Qisexingtai hand diagnostic method in diagnosis of coronary artery disease.
- Effect of Tongguan Capsules () on Restenosis after Coronary Stent Implantation: Study Protocol for A Randomized Controlled Trial.
- Chemical profile and potential mechanisms of Huo-Tan-Chu-Shi decoction in the treatment of coronary heart disease by UHPLC-Q/TOF-MS in combination with network pharmacology analysis and experimental verification.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status4
- The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients
- Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
- Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- Syndrome Differentiation in the Management of Chronic Stable Coronary Artery Disease (SCAD) to Improve Quality
Other diseases
Congenital heart disease
先天性心脏病Led 7 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Guangzhou for congenital heart disease207 hospitals in China for congenital heart disease
No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Papers it led7
- The deficiency of DIP2C leads to congenital heart defects in patients with 10p15.3 microdeletion syndrome.
- MitraClip used for severe mitral regurgitation after surgery for type A aortic dissection combined with Marfan syndrome.
- Transversus Thoracis Muscle Plane Block in Paediatric Patients Who Underwent Minimally Invasive Closure of Transthoracic Ventricular Septal Defect: A Retrospective Study.
- Identification of a Novel 15q21.1 Microdeletion in a Family with Marfan Syndrome.
- Loeffler's group 2 cor triatriatum sinistrum with mobile left atrial thrombus - a case report and literature review.
- Novel insertion mutation (Arg1822_Glu1823dup) in MYH6 coiled-coil domain causing familial atrial septal defect.
- Efficacy and safety of the Amplatzer Duct Occluder II for ventricular septal defect closure: a meta-analysis.
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
12 hospitals in Guangzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
20 hospitals in Guangzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Lymphangioleiomyomatosis
肺淋巴管平滑肌瘤病Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Guangzhou for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis
No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 4 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Guangzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Semen Strychni Pulveratum and vomicine alleviate neuroinflammation in amyotrophic lateral sclerosis through cGAS-STING-TBK1 pathway.
- Circulating Levels of T-Cell Traits and the Risk of Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study.
- Ginsenoside-Rg1 combined with a conditioned medium from induced neuron-like hUCMSCs alleviated the apoptosis in a cell model of ALS through regulating the NF-κB/Bcl-2 pathway.
- Exploring the mechanism of Semen Strychni in treating amyotrophic lateral sclerosis based on network pharmacology.
Other diseases
IgA nephropathy
IgA 肾病Led 6 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
16 hospitals in Guangzhou for IgA nephropathy300 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led6
- Moderate to severe chronic arteriolar lesions is an independent risk factor for adverse renal outcomes in IgA nephropathy.
- Nomogram for the prediction of crescent formation in IgA nephropathy patients: a retrospective study.
- The role of urine IgG in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis.
- Prediction of prognosis in immunoglobulin a nephropathy patients with focal crescent by machine learning.
- Comparison between outcomes of IgA nephropathy with nephrotic-range proteinuria and nephrotic syndrome: do podocytes play a role?
- Volume of Crescents Affects Prognosis of IgA Nephropathy in Patients without Obvious Chronic Renal Pathology.
Earlier papers (2016–2020)4
- MicroRNA-27a-3p directly targets FosB to regulate cell proliferation, apoptosis, and inflammation responses in immunoglobulin a nephropathy.
- Small RNA deep sequencing reveals novel miRNAs in peripheral blood mononuclear cells from patients with IgA nephropathy.
- Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review.
- Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Guangzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
Earlier papers (2016–2020)3
- Daifan San intervenes in forkhead box P3 and the interleukin (IL)-23/IL-17A signaling pathway to help prevent and treat primary biliary cirrhosis.
- CD19+CD24hiCD38hi B Cell Dysfunction in Primary Biliary Cholangitis.
- Elevated circulating CD14lowCD16+ monocyte subset in primary biliary cirrhosis correlates with liver injury and promotes Th1 polarization.
Getting in touch
Name card to show staff or a driver
广东省中医院
Guangdong Provincial Hospital of Chinese Medicine
广州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR Wikidata
Guangdong Provincial Hospital of Traditional Chinese Medicine; Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Traditional Chinese Medicine (W.W; Guangdong Provincial Hospital of Traditional Chinese Medicine (GPHTCM); Second Clinical College of Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine (Hainan Hospital); GDHCM; Guangdong Hospital of Traditional Chinese Medicine